Goodwin Biotechnology, Inc. (GBI) has completed the expansion of its cGMP manufacturing space, doubling its capacity. The expansion includes the addition of a 200L and 500L stirred tank bioreactor train to its hollow fiber and perfusion capabilities, and is in response to the growing industry needs for biological manufacturing.
    
Stephanie Finnegan, GBI’s chief executive officer, said, “This is the culmination of a dream we envisaged a decade ago.  This was finally made possible by the investment and support of our parent company, Wallace Pharmaceuticals. Our team is eager to scale up our operations to manufacture life-saving therapeutics for late-stage clinical trials. We are proud to be an integral component of the rapidly growing biopharmaceutical presence in Florida.”
   
GBI manufactures a monoclonal antibody, NPC-1C for advanced pancreas cancer, for Neogenix, as well as Q Therapeutics’ IgM antibody, a component used in the isolation of stem cells to treat diseases of the central nervous system. Also, a growing service area for GBI involves the conjugation of antibodies and recombinant proteins to various linkers to be used in radio-immunotherapy and the delivery of chemotoxins in small doses directly to the patients’ cancer sites.  
    
“On behalf of Neogenix Oncology, I would like to extend our congratulations to the team at Goodwin Biotech. Completing a major expansion like this is a major undertaking, and its completion marks an important milestone in the company’s growth and development. We are particularly pleased to be working with a group of such dedicated and talented individuals, and we all look forward to the day when cancer patients will benefit from our hard work,” said Tom Lytle, chief operating officer, Neogenix Oncology.